EFFECTIVENESS OF IL-23 INHIBITORS IN PATIENTS WITH MODERATE–SEVERE CHRONIC PLAQUE PSORIASIS

Peláez Bejarano A, Montero Pérez O, García Giménez I.
JUAN RAMON JIMENEZ HOSPITAL, PHARMACY, HUELVA, SPAIN.

BACKGROUND

Inhibitors of interleukin-23 (IL-23 inhibitors) have emerged as safe and effective options for the treatment of moderate-to-severe plaque psoriasis. These drugs are contributing to a rising standard for psoriasis outcomes through resolution of skin lesions and joint manifestations and improvement of patient quality of life.

AIM AND OBJECTIVES

To evaluate the effectiveness of IL-23 inhibitors in patients with moderate–severe chronic plaque psoriasis.

MATERIAL AND METHODS

• Observational study
• Patients with moderate-to-severe psoriasis who were treated for at least 36 weeks with IL-23 inhibitors.
• Data collected: demographic characteristics and previous biological therapies.

RESULTS

35 patients were included: 21 women (60%) and mean age 50.6±13.8 years

Mean PASI at baseline was 10.1±5

Evolution of the PASI score

Evolution of the number of patients achieving PASI 75, 90 and 100 responses

CONCLUSIONS AND RELEVANCE

IL-23 inhibitors show great results in the management of moderate-to-severe psoriasis in adults. Results of the real-life study are consistent with the pivotal trials.